NCT04494815View on ClinicalTrials.gov

A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 18, 2020

Primary Completion Date

May 31, 2022

Study Completion Date

July 31, 2022

Conditions
Peripheral Neuropathic Pain
Interventions
DRUG

SR419

Each participant will receive 1 dose of 20 mg SR419 oral suspension.

DRUG

active control

Each participant will receive 1 dose of 300 mg active control capsule.

DRUG

SR419 placebo

Each participant will receive 2 doses of SR419 placebo oral suspension.

DRUG

active control placebo

Each participant will receive 2 doses of active control placebo capsule.

Trial Locations (1)

5000

Clinical Research Facility Medical School, University of Adelaide, Adelaide

All Listed Sponsors
lead

Shanghai SIMR Biotechnology Co., Ltd.

INDUSTRY

NCT04494815 - A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419 | Biotech Hunter | Biotech Hunter